127 filings
8-K
ANTH
Anthera Pharmaceuticals Inc
9 Jul 18
Anthera Pharmaceuticals Announces SEC Deregistration
4:39pm
8-K
ANTH
Anthera Pharmaceuticals Inc
27 Jun 18
Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request
4:12pm
8-K
ANTH
Anthera Pharmaceuticals Inc
18 Jun 18
Departure of Directors or Certain Officers
4:30pm
8-K
ANTH
Anthera Pharmaceuticals Inc
30 May 18
Other Events
5:25pm
8-K
ANTH
Anthera Pharmaceuticals Inc
23 May 18
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:25pm
8-K
czgxz c6w21pur
16 Apr 18
Cost Associated with Exit or Disposal Activities
12:00am
8-K
jejsvac
12 Mar 18
Anthera Pharmaceuticals Reports Top Line Data from
12:00am
8-K
xrfvifskmls0ea3si9
5 Mar 18
Anthera Pharmaceuticals Provides Business Update and Reports
12:00am
8-K
zqlz7azkbyn9d
25 Jan 18
Anthera Receives Positive Nasdaq Listing Determination
12:00am
8-K
5lo oexb80ei
9 Jan 18
Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering
12:00am
8-K
h41qonbebt3i3sv
17 Nov 17
Anthera Pharmaceuticals Announces Expected Receipt of Nasdaq Listing Determination Notice
12:00am
8-K
c2prnv3q
6 Nov 17
Anthera Pharmaceuticals Provides Business Update
12:00am
8-K
9o5cfdni61d1cb
25 Oct 17
Anthera Pharmaceuticals Announces Pricing of $15 Million Private Placement Offering
12:00am
8-K
83scra
28 Aug 17
Anthera Announces Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy
12:00am
8-K
723xio 1h8
9 Aug 17
Other Events
12:00am
8-K
aurkjor19uuv2lyq5s4
9 Aug 17
Anthera Pharmaceuticals Provides Business Update
12:00am
8-K
0bxoe2wyk6jp6i5e7hd
14 Jul 17
Departure of Directors or Certain Officers
12:00am
8-K
lv1i9 xnr3wleh79v
19 Jun 17
Entry into a Material Definitive Agreement
12:00am
8-K
l4bc3 9fh2rxf
25 May 17
Other Events
12:00am
8-K
b7y0kth
18 May 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am